Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists (PIVICOG-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01007864
Recruitment Status : Completed
First Posted : November 4, 2009
Last Update Posted : May 24, 2012
FGK Clinical Research GmbH
Information provided by (Responsible Party):
Desitin Arzneimittel GmbH

Brief Summary:

The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with Parkinson's disease in comparison with other oral non-ergot dopamine agonists.

It should be tested whether piribedil is superior to continued pramipexole or ropinirole treatment regarding improvement of reduced vigilance and cognitive performance in patients with Parkinson's disease.

Condition or disease Intervention/treatment Phase
Idiopathic Parkinson's Disease Drug: piribedil Drug: pramipexole or ropinirole Phase 3

Detailed Description:

Treatment of motor symptoms associated with PD by non-ergot dopamine agonists has been proven to be effective, both as monotherapy and in combination with levodopa. Non-motor symptoms like cognitive or sleep-related disorders and disturbed vigilance, however, are common in PD and can significantly worsen health and quality of life of the patient and family members. Some of these non-motor symptoms may also be caused by the antiparkinsonian medication per se. The Committee for Proprietary Medicinal Products (CPMP) initiated a review of dopamine agonists in relation to episodes of sudden onset of sleep already in 2000 which resulted in special warnings of somnolence and sudden sleep attacks in the non-ergot dopamine agonists' summary of product characteristics.

Beneficial effects of piribedil on parameters of vigilance and cognition have been described in several studies. But, as it seems, no study has been performed so far to identify such effects in the setting of a comparative study with different oral non-ergot dopamine agonists in patients with PD, and utilizing vigilance and cognitive parameters as primary and main secondary objective. The neuropsychological tests being applied in this study are validated and routinely used tests in studies investigating different aspects of attention or vigilance and cognition.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists
Study Start Date : January 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: piribedil Drug: piribedil
Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
Other Name: Clarium®

Active Comparator: pramipexole or ropinirole Drug: pramipexole or ropinirole
continuation of pre-study treatment regimen

Primary Outcome Measures :
  1. The primary efficacy variable will be the 'median reaction time during the second 15 minutes (minutes 16-30)' of the subtest 'vigilance', visual test condition 'moving bar', of the Test battery for Attention Performances (TAP) at end of treatment. [ Time Frame: Baseline and End of Treatment ]

Secondary Outcome Measures :
  1. Other vigilance parameters of the TAP test [ Time Frame: Baseline and End of Treatment ]
  2. Other neuropsychological tests: Test of verbal fluency (RWT), Verbal learning memory test (VLMT), Stroop test (FWIT) [ Time Frame: Baseline and End of Treatment ]
  3. Epworth Sleepiness Scale (ESS) [ Time Frame: Baseline and End of Treatment ]
  4. Parkinson's Disease Sleeping Scale (PDSS) [ Time Frame: Baseline and End of Treatment ]
  5. Unified Parkinson's Disease Rating Scale (UPDRS) subscores I to IV and total score [ Time Frame: Baseline and End of Treatment ]
  6. Parkinson's disease quality of life questionnaire (PDQ-39) [ Time Frame: Baseline and End of Treatment ]
  7. Clinical Global Impressions (CGI) (except item 3.2) [ Time Frame: End of Treatment ]
  8. Patient Global Impression (PGI) [ Time Frame: End of Treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female Caucasian patients aged 35 to 80 years;
  • Patients with idiopathic Parkinson's disease;
  • Hoehn & Yahr stages 1 to 4;
  • Stable medication with anti-parkinsonian medication, including stable treatment with pramipexole or ropinirole, for at least 4 weeks prior to Screening;
  • Significant daytime sleepiness: Epworth Sleepiness Scale score equals or is higher than 11 under previous therapy with pramipexole or ropinirole;
  • Patients who have read and understood the patient information sheet and have provided a signed written informed consent form;
  • Patients are considered to be compliant to the study regimen.

Exclusion Criteria:

  • Treatment of Parkinson's disease with any dopamine agonist other than pramipexole or ropinirole within 4 weeks prior to Screening;
  • Known hypersensitivity to Clarium® or its excipients;
  • Patients with daytime sleepiness caused by other factor's than Parkinson's disease, i.e., idiopathic narcolepsy, shift work, severe alcohol abuse, obstructive diseases, sleep apnea syndrome, or Periodic limb movement disorder;
  • Secondary and atypical Parkinson syndrome;
  • Depression (Beck Depression Inventory score higher than 16);
  • Dementia (Mini-Mental State Examination score equals or is lower than 24);
  • Severe disability in extremities which could influence clinical assessments;
  • Clinically significant disease concerning the lung, liver or kidney;
  • Any acute or chronic infection that may influence the outcome of the study;
  • Cardiovascular shock;
  • Acute myocardial infarction;
  • Congestive heart failure NYHA class III or IV;
  • Uncontrolled arterial hypertension (diastolic blood pressure equals or is higher than 105 mmHg) or clinically relevant hypotension;
  • Evidence of clinically active cancer;
  • Color vision defect that may have impact on assessment of FWIT;
  • History of substance abuse;
  • Intake of benzodiazepines (or derivates) if not at stable dose for at least 4 weeks prior to Screening; intake of antiallergic agents (H1 receptor antagonists, except selective, non-sedating H1-antihistamines, e.g. loratadine and others), substances with psychostimulant properties (e.g., amphetamine, modafinil), or antidepressants if not at stable dose for at least 2 months prior to Screening;
  • Current treatment with neuroleptic agents (except for clozapine);
  • Female patients who are pregnant or lactating;
  • Female patients of childbearing potential who do not use a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly), e.g., implants, injectables, combined oral contraceptives in combination with a barrier method, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner;
  • Mental condition rendering the patient unable to understand the nature, scope and possible risks of the study;
  • Patient has a history of or is suspicious of unreliability, poor co-operation or non-compliance with medical treatment;
  • Patients are currently or previously (within the last 28 days) participating in another study of an investigational drug;
  • Patients who were previously enrolled in this study;
  • Patients with known Hepatitis B or C or HIV infection;
  • Patients who are employees of the sponsor or patients who are employees or relatives of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01007864

Ulm, Baden-Württemberg, Germany, 89081
Wolfach, Baden-Württemberg, Germany, 77709
München, Bayern, Germany, 80804
Berlin-Steglitz, Berlin, Germany, 12163
Marburg, Hessen, Germany, 35043
Göttingen, Niedersachsen, Germany, 37075
Dresden, Sachsen, Germany, 01307
Leipzig, Sachsen, Germany, 04107
Gera, Thüringen, Germany, 07551
Stadtroda, Thüringen, Germany, 07646
Berlin, Germany, 12200
Berlin, Germany, 13353
Sponsors and Collaborators
Desitin Arzneimittel GmbH
FGK Clinical Research GmbH
Study Director: Martina Wangemann, Dr. Desitin Arzneimittel GmbH

Responsible Party: Desitin Arzneimittel GmbH Identifier: NCT01007864     History of Changes
Other Study ID Numbers: PIR-007/K
First Posted: November 4, 2009    Key Record Dates
Last Update Posted: May 24, 2012
Last Verified: April 2012

Keywords provided by Desitin Arzneimittel GmbH:
dopamine agonist

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Dopamine Agents
Dopamine Agonists
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Dermatologic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating